SBIR/STTR Research Award
Catalytic Synthesis of Arylboronic Esters
Award amount
$100,000Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MEDICHEM LIFE SCIENCES
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): The usefulness of arylboronic acids or
esters in organic synthesis, biology and molecular recognition leads to the
origin of this proposal. Classical preparations of arylboronic acids use harsh
conditions that can only be tolerated by a very limited number of functional
groups.
In the past five years, the appearance of new technology has opened the door to
the preparation of arylboronic esters with a broader functional group
tolerance, although current progress is still limited with respect to yield and
substrate specificity. We propose to develop a series of transition metal-based
catalysts with the intention of screening for one with high efficiency,
practical scalability and broad functionality. In Phase I, we will synthesize a
series of ligands and the corresponding complexes. Then we will evaluate the
catalytic capability of these complexes as catalysts, based on a standard model
reaction. Once the best catalyst is selected, the reaction will be optimized
based on reagents, solvents, temperature and additives by using a combinatorial
approach coupled with Design of Experiments (DOE) software. In Phase Il, we
will expand the use of various substrates for the synthesis of arylboronic
esters. If necessary, we will modify the best catalysts and optimize the
synthetic method.
PROPOSED COMMERCIAL APPLICATION:
Arylboronic acids and esters are very important chemical intermediates that are used by
pharmaceutical and the related industry in large quantities. The classical preparations of arylboronic acids use harsh conditions that can only be tolerated by a very limited amount
of functional groups. MediChem proposes a highly efficient catalytic process to synthesize
arylboronic esters or acids with practical scalability and a wide range of functionality that
may be commercialized for application in academia and industry.
Technology keywords
Not reported